Specialities

Specialities

Bladder Cancer
Breast Cancer
Colorectal Cancer
COVID-19
Dermatological Cancers
Diagnostics and Screening
Gastrointestinal Cancers
Genitourinary Cancer
Gynaecological Cancers
Haematological Malignancies
Haematology
Head and Neck Cancer
Immunotherapy
Leukaemia
Lung Cancer
Lymphoma
Multiple Myeloma
Endocrine Cancers
Ovarian Cancer
Pancreatic Cancer
Paediatric Oncology
Policy
Prostate Cancer
Renal Cancer
Sarcoma
Supportive Cancer Care
Soft Tissue Tumours
Neuro-oncology
Radiology
Radiotherapy
Rare Diseases
Search

Trending Topic

3d illustration of human body liver
12 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Durvalumab for the Treatment of Advanced Biliary Tract Cancer test

Allan A Lima Pereira, Gabriel Lenz, Tiago Biachi de Castria

Despite being considered a rare type of malignancy, constituting only 3% of all gastrointestinal cancers, the incidence of biliary tract cancers (BTCs) has been increasing worldwide in recent years, with about 20,000 new cases annually only in the USA.1–3 These cancers arise from the biliary epithelium of the small ducts in the periphery of the liver […]

touchREVIEWS in Oncology & Haematology. 2025;21(1):Online ahead of journal publication

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin

CME Accredited Learning

Our accredited content is designed to impact patient health outcomes, by ensuring that it provides you with a learning experience that will positively impact your clinical practice, based on adult learning preferences and intuitive instructional design. All activities are developed in collaboration with leading faculty and education partners.

touchONCOLOGY

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
54 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchSYMPOSIUM

Navigating the clinical impact of TROP2-targeting in NSCLC

Prof. Marina Garassino, Prof. Jaruskha Naidoo, Prof. David Planchard

In this symposium, three lung cancer specialists share their insights on TROP2-targeted ADCs in NSCLC

33 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchMDT

ADCs in metastatic breast cancer: Managing toxicities and optimizing quality of life

Dr Véronique Diéras, Dr Scott Edwards, Dr Kayla Freeman, Mrs Lesley Turner

A multidisciplinary team and a patient advocate discuss antibody–drug conjugate (ADC) related toxicities in metastatic breast cancer.

Translations available:
36 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchMDT

PARP inhibitors for metastatic castration-resistant prostate cancer: Enhancing patient–practitioner conversations

Dr Alicia Morgans, Prof. Albrecht Stenzinger, Dr Grace Cullen, Mr Tony Collier

A multidisciplinary team and a patient advocate discuss use of PARP inhibitors in mCRPC

Translations available:
35 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchIN CONVERSATION

Cervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individuals

Dr Marc Steben, Dr Barbara Moscicki

Watch two experts discuss HPV-related disease, vaccination scheduling and strategies to increase uptake.

Translations available:
15 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchFOCUS

Looking to the future in the treatment of steroid-refractory chronic GvHD

Dr Corey Cutler

Expert insights on new and emerging approaches to optimize the management of steroid-refractory cGvHD.

55 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchCONGRESS

Updates in BCMA-directed therapies in multiple myeloma from ASH 2024

Prof. Katja Weisel, Dr Nisha Joseph, Prof. Roman Hájek

Three experts discuss data presented at ASH 2024 on BCMA-targeting agents in multiple myeloma.

Translations available:
40 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION

What's new in primary ITP? Key updates from ASH 2024

Dr Hanny Al-Samkari, Dr Drew Provan, Dr Barbara Skopec

Three expert haematologists discuss current and emerging treatments for ITP as well as the disease burden.

Translations available:
29 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT OPINIONS

RAS mutations and personalized cancer care: Targeting the future

Dr David S Hong, Dr Eileen M O’Reilly, Dr Rebecca S Heist

Experts discuss the role of RAS mutations in solid tumours and how they may be targeted to improve outcomes.

Translations available:
20 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchFOCUS

Focused insights: Data implications of ADCs in NSCLC treatment

Prof. Céline Mascaux

Watch a lung cancer expert discuss the latest data for ADCs in NSCLC and their implications for clinical practice.

Society & Congress Partners

touchONCOLOGY is proud to partner with leading medical societies and congresses from around the world to bring you news and insight from virtual and live events

View All
90 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchSYMPOSIUM

Collaboration in chronic ITP: Improving quality of life and patient outcomes

Prof. Cindy Neunert, Prof. David Kuter, Dr María Eva Mingot Castellano

Leading experts discuss the impact of ITP on patients and review current and emerging treatment strategies.

35 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT FOCUS

Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life

Dr AeRang Kim, Dr Rebecca Brown, Dr Kaleb Yohay

Three experts share insights into the treatment and care of patients with NF1 from childhood to adulthood.

36 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT OPINIONS

Advancing the treatment of muscle-invasive bladder cancer: Updates on immunotherapy in the perioperative setting

Dr Laura Mertens; Prof. Thomas Powles; Ms Lindsay Diamond

An oncologist, urologist and oncology nurse consider the use of perioperative immunotherapy in MIBC.

Translations available:
33 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT OPINIONS

Navigating treatment choices in high-risk early-stage melanoma

Dr Teresa Amaral, Prof. Piotr Rutkowski, Dr Tina Hieken

Hear expert insights on recurrence risk in early-stage melanoma and possible treatment approaches

Translations available:
99 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchCLINICAL PERSPECTIVES

Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease

Dr Helena Yu, Dr Antonio Passaro, Dr Aaron Lisberg, Dr Sara Pilotto, Ms Jackie Fenemore, Prof. Egbert Smit

Experts provide insights on tailoring treatment in patients with EGFR-mutant and wildtype NSCLC.

Translations available:
39 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchMDT

Where to next in limited-stage small cell lung cancer? The role of immune checkpoint inhibitors

Dr Lizza Hendriks, Dr Jacob Sands, Prof. Suresh Senan

A multidisciplinary team discusses the role of immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC).

Translations available:
55 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchMDT

Precision targeting of MET in NSCLC: A multidisciplinary approach

Dr Xiuning Le, Dr Christine Argento, Dr Sandra Cuellar, Ms Stephanie McDonald, Prof. Albrecht Stenzinger

A multidisciplinary team of specialists discuss the use of targeted therapies for NSCLC with MET alterations.

15 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchFOCUS

Targets in early NSCLC: A focus on EGFR-mutant treatment options

Dr Jennifer Carlisle

Watch an expert in lung cancer discuss the treatment options for patients with early-stage EGFR-mutant NSCLC

55 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchCONGRESS

Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024

Prof. María-Victoria Mateos, Dr Rakesh Popat, Prof. Evangelos Terpos

Three experts discuss data presented at COMy and EHA 2024 on BCMA-targeting agents in multiple myeloma.

Translations available:
Load More...

All touchIME CME activities are accredited. Learners can claim ACCME, ANCC, ACPE or EBAC credits upon completion of the activities. This content is for healthcare professionals only.

Latest Medical Education - straight to your inbox

Close Popup